

C1 Inhibitor function

C1 Inhibitor (C1Inh) function kit is based on an innovative assay targeting kallikrein for C1Inh deficiency Angioedema (AE). C1Inh is the major control of contact phase proteases (FXIIa and Kallikrein), it is also involved in the control of complement, coagulation and fibrinolysis proteases. The new target improve the test sensitivity because it is developed according the physiopathology of the Angioedema disease. This better sensitivity allow the detection of Angioedema with transitory and intermediate C1Inh deficiency (e.g. AE induced by estrogen).




Format

- Enzymatic kinetics followed by spectrophotometry
- Chromogenic substrate
- 96 well microplate with sufficient reagents to test 32 patients (2*16) in duplicate
- 5 point standard curve
- Sample type: citrate plasma
- Controls: High & Low

Assay Performance


- Limit of detection: 0.01 IU/mL
- Limit of quantification: 0.02 IU/mL
- Read out: spectrophotometry 405 nm, 15 min, 30°C
- Cut-off value (IU/mL):

Female	< 0.36
Male	< 0.61



C1 Inhibitor function

ROC



Diagnostic performance

- BK Angioedema (BK-AE) sensitivity: 94% (♀), 100% (♂) and specificity: 99% (♀), 100% (♂)
- C1Inh function data using kallikrein as target are in line with immune-blotting results of C1Inh species

Benefits

- Excellent assay performances, providing features suitable for Angioedema diagnostic or follow-up.
- Detects female Angioedema with estrogen-dependent trigger
- Good sensitivity allows following up of patients with intermediate C1Inh deficiency, during active periods and after inducer withdrawal (e.g. estrogen).

